01 Supply chain disruptions are expected to have a moderate impact on the breast biopsy devices market share due to shortages of biopsy needles, medical-grade materials, and specialized components. The market is expected to experience a K-shaped recovery, as established manufacturers can maintain supply through diversified production networks. Smaller manufacturers remain more exposed to component shortages and procurement delays. The market is projected to grow at a CAGR of 6.54%. Supply constraints could temporarily reduce growth by an illustrative 1.4 percentage points to 5.14%. Improved component availability and manufacturing capacity are expected to support a gradual return to 6.54% growth.
01 Adoption of Contrast-Enhanced Breast Biopsy The breast biopsy devices market analysis indicates increasing adoption of contrast-enhanced mammography-guided biopsy systems for sampling suspicious breast lesions. These systems help radiologists identify lesions that are difficult to detect through conventional imaging. For example, Hologic and GE HealthCare offer breast imaging and biopsy solutions that support image-guided breast diagnostic procedures.
02 Integration of MRI-Compatible Vacuum-Assisted Biopsy Systems MRI-compatible vacuum-assisted biopsy systems are gaining attention for sampling breast lesions that are difficult to identify through conventional imaging. Manufacturers are developing compact systems suitable for use inside MRI examination rooms. These devices allow clinicians to collect tissue samples while remaining close to the patient.
01 In April 2026, Merit Medical Systems acquired View Point Medical for approximately USD 140 million, including assumed liabilities. View Point develops the OneMark Detection Imaging System and tissue markers that help localize breast and soft-tissue lesions around biopsy and subsequent treatment.
01 Detection of Breast Abnormalities through Advanced Screening and Demand for Single-Use Breast Biopsy Instruments Drives Market Wider use of digital breast tomosynthesis is increasing the detection of abnormalities requiring diagnostic evaluation. Improved imaging helps identify small lesions that may need image-guided tissue sampling. The FDA's breast density reporting requirements have also strengthened awareness of additional diagnostic assessment. These developments support demand for stereotactic and ultrasound-guided biopsy devices, particularly in breast imaging centers handling suspicious mammography findings.Preference for single-use breast biopsy instruments is strengthening demand for disposable biopsy needles and sampling accessories. Healthcare facilities require sterile instruments for each procedure to minimize cross-contamination risks. Single-use devices eliminate the need for cleaning and sterilization between procedures, reducing equipment turnaround time. The use of disposable components in core needle biopsy systems supports recurring product demand and steady revenue generation for breast biopsy device manufacturers.
01 Shortage of Specialized Biopsy Needles and High Equipment Costs and Limited MRI-Guided Biopsy Access Restrain Market Growth Limited availability of specialized breast biopsy needles is affecting procedure scheduling and device utilization. Healthcare facilities depend on compatible disposable needles for stereotactic biopsy systems. Supply disruptions can delay tissue sampling and increase procurement difficulties. The U.S. FDA has identified a shortage of stereotactic breast biopsy needles, with the disruption expected to continue through the first quarter of 2027.MRI-guided breast biopsy requires specialized equipment and trained radiologists, increasing the financial burden on diagnostic facilities. Smaller hospitals may face difficulties establishing dedicated biopsy services due to equipment and maintenance expenses. The American College of Radiology recognizes that limited access to MRI-guided biopsy can require patients to undergo repeat imaging at another facility.
01 Expansion of Advanced Vacuum-Assisted Tissue Sampling Systems and Development of Advanced Breast Biopsy Site Markers Creates Growth Opportunities Advancements in vacuum-assisted biopsy technology are creating opportunities for manufacturers to improve tissue collection efficiency. These systems allow multiple samples to be collected through a single needle insertion, reducing repeated needle placement. According to RadiologyInfo, a service of the American College of Radiology and Radiological Society of North America, vacuum-assisted procedures typically collect 8–10 tissue samples.Development of advanced breast biopsy site markers is creating opportunities for manufacturers to improve lesion localization after tissue sampling. Hydrogel-based markers offer improved visibility during ultrasound examinations and help identify previously biopsied areas. These markers also support accurate localization when lesions become difficult to identify after treatment. Manufacturers can expand their portfolios with nonmetallic and migration-resistant markers, supporting demand for specialized breast biopsy accessories.